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Abstract 1 
Background. Long-lasting insecticidal nets (LLINs) are the primary malaria prevention tool, but their 2 
effectiveness is threatened by pyrethroid resistance. We embedded a pragmatic cluster-randomised 3 
trial into Uganda’s national LLIN campaign to compare conventional LLINs to LLINs containing 4 
piperonyl butoxide (PBO), a synergist that can partially restore pyrethroid susceptibility in mosquito 5 
vectors.  6 
 7 
Methods. Overall, 104 clusters (health sub-districts) were included, covering 40% of Uganda. 8 
Proportionate randomisation was used to assign clusters to one of four arms, including LLINs with 9 
PBO (32 PermaNet 3·0, 20 Olyset Plus), and conventional LLINs (37 PermaNet 2·0, 15 Olyset Net). At 10 
baseline, 6, 12, and 18 months after LLIN distribution, cross-sectional surveys were conducted in 50 11 
randomly selected households per cluster (5,200 per survey); a sub-set of 10 households per cluster 12 
(1,040 per survey) were randomly selected for entomology surveys. The primary outcome was 13 
parasite prevalence by microscopy in children aged 2-10 years. 14 
 15 
Findings. LLINs were delivered from March 2017 to March 2018. In the ‘as treated’ analysis, three 16 
clusters were excluded because no dominant LLIN was received, and four clusters were reassigned, 17 
resulting in 49 PBO LLIN (31 PermaNet 3·0, 18 Olyset Plus) and 52 non-PBO LLIN clusters (39 18 
PermaNet 2·0, 13 Olyset Net). At six months, parasite prevalence was 11% in the PBO arm vs 15% in 19 
the non-PBO arm (prevalence ratio [PR] adjusted for baseline values 0·74 [95% CI: 0·62–0·87], 20 
p<0·001). Results were similar at 12 months (11% vs 13%, PR 0·73 [95% CI: 0·63–0·85], p<0·001) and 21 
at 18 months (12% vs 14%, PR 0·84 [95% CI: 0·72–0·98], p=0·03).  22 
 23 
Interpretation. In Uganda, where pyrethroid resistance is high, PBO LLINs reduced parasite 24 
prevalence more effectively than conventional LLINs for up to 18 months.  25 
 26 
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 29 
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ISRCTN, ISRCTN17516395. Registered 14 February 2017, https://doi.org/10.1186/ISRCTN17516395  31 
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Research in context 35 
 36 
Evidence before this study 37 
We searched titles and abstracts in PubMed with the terms ‘piperonyl butoxide, PBO, Olyset* or 38 
PermaNet*’, and ‘insecticide-treated bednets, nets, bednet*, ITN*, LLIN*, insecticide-treated 39 
bednet*, or insecticidal net*’ for studies published in English. We found one trial that evaluated the 40 
impact of long-lasting insecticidal nets (LLINs) with piperonyl butoxide (PBO) on epidemiological 41 
outcomes in Tanzania. This cluster-randomised, controlled trial compared Olyset® Plus (LLINs with 42 
PBO) to Olyset® Net (LLINs without PBO) in a single district of Tanzania, where pyrethroid resistance 43 
is high. At 9, 16, and 21 months after LLIN distribution, prevalence of malaria parasites was lower in 44 
community residents who received PBO LLINs, than in those who received conventional (non-PBO) 45 
LLINs. Supported largely by these results, the World Health Organization (WHO) provided an interim 46 
endorsement of PBO LLINs in 2017, recommending their use in areas where pyrethroid resistance is 47 
mediated by metabolic mechanisms and is classified by moderate intensity using standard 48 
procedures. A Cochrane systematic review published in 2018 assessed the effectiveness of PBO LLINs 49 
on epidemiologic and entomologic outcomes. Fifteen studies were included; two laboratory trials, 50 
eight experimental hut trials, and five cluster-randomised controlled village trials, including the 51 
Tanzanian trial, which was the only study to report epidemiologic outcomes. This review suggested 52 
that PBO LLINs would be most effective in areas of high-level pyrethroid resistance; the effectiveness 53 
of PBO LLINs in areas of moderate or low-level pyrethroid resistance was less clear. Further 54 
epidemiological evidence of the effectiveness of PBO LLINs is urgently needed to guide WHO 55 
recommendations and malaria control policy throughout Africa, where pyrethroid resistance in 56 
malaria vectors is widespread. 57 
 58 
Added value of this study 59 
This study makes an important contribution to the limited evidence base on use of PBO LLINs. In this 60 
large, cluster-randomised, controlled trial we found that PBO LLINs provided superior protection 61 
against malaria in the setting of high-level insecticide resistance in Uganda. Both PBO and non-PBO 62 
LLINs effectively reduced parasite prevalence from baseline, suggesting that conventional LLINs 63 
provide protection and may still have a role in settings where insecticide resistance and malaria 64 
transmission are lower. This innovative trial, embedded within a national LLIN distribution campaign, 65 
serves as a paradigm for future assessment of malaria control interventions. 66 
 67 
Implications of all the available evidence 68 
This study provides the evidence needed to support WHO’s final recommendation on use of PBO 69 
LLINs. LLINs are the cornerstone of malaria control in Africa. Deploying PBO LLINs in areas of high-70 
level pyrethroid resistance will help to extend the useful lifespan of this important vector control 71 
tool.  72 
 73 
 74 
  75 
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Introduction 76 
Long-lasting insecticidal nets (LLINs) are the foundation of malaria control in sub-Saharan Africa.1,2 77 
Over the past twenty years, substantial efforts have been made to expand LLIN coverage in malaria 78 
endemic countries. From 2000-2015, the incidence of Plasmodium falciparum fell by 40% in Africa, 79 
largely attributable to widespread use of LLINs.3 However, the effectiveness of LLINs is threatened by 80 
pyrethroid resistance, which could severely compromise malaria control efforts.4 Recent reports 81 
suggest that malaria control has stalled in Africa, particularly in high burden areas.5 The World 82 
Health Organization (WHO) has called for aggressive action to preserve malaria control gains and to 83 
ensure that the ambitious 2030 targets, including eliminating malaria from at least 35 countries, are 84 
met.6 To achieve this, effectiveness of LLINs must be maintained. 85 
 86 
Currently, all LLINs are impregnated with pyrethroid insecticides, due to their favourable safety 87 
profile, low cost and rapid insecticidal activity.7 However, resistance to pyrethroids is now 88 
widespread in Africa.8 In African Anopheles mosquitoes, pyrethroid resistance is primarily mediated 89 
through two mechanisms; ‘knock down resistance’ (kdr) caused by mutations in the voltage-gated 90 
sodium channel where pyrethroids bind, and metabolic resistance resulting from alterations in 91 
enzymes that detoxify pyrethroids, notably cytochrome P450s.9,10 To address P450-based resistance, 92 
newer LLINs combine pyrethroids with a synergist, piperonyl butoxide (PBO), which inhibits P450s 93 
enzymes, blocking the mosquito’s defence against pyrethroids and at least partially restoring 94 
pyrethroid susceptibility.11  95 
 96 
A systematic review of PBO LLINs found that they were associated with higher mosquito mortality 97 
and lower blood-feeding rates in areas of high-level insecticide resistance, as compared to non-PBO 98 
LLINs.12 A cluster-randomised, clinical trial of the effectiveness of a PBO LLINs (Olyset Plus), 99 
conducted in Tanzania, found that PBO LLINs were associated with lower parasite prevalence, than 100 
conventional LLINs, at 9, 16, and 21 months after distribution.13 Subsequently, the WHO issued an 101 
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interim endorsement of PBO LLINs, recommending them for areas of intermediate-level pyrethroid 102 
resistance, due at least partly to metabolic mechanisms.14 However, the Tanzanian study had several 103 
limitations: the study was restricted to one district; parasite prevalence was measured using rapid 104 
diagnostic tests, which may have variable specificity;15 insecticide resistance was assessed by kdr 105 
mutations, not markers of metabolic resistance; and 21-month data were potentially compromised 106 
by routine distribution of new LLINs within the study area. Thus, additional epidemiological evidence 107 
of PBO LLINs in different contexts is urgently needed to support robust guidance to countries. 108 
 109 
In Uganda, despite mass distribution of LLINs, targeted indoor residual spraying (IRS), and treatment 110 
of symptomatic malaria cases with artemisinin-based combination therapies, progress on malaria 111 
control has been slow and control gains have been difficult to sustain.16,17 Recently, malaria cases in 112 
Uganda have increased, underscoring the need to intensify malaria control efforts.5 The Ministry of 113 
Health has committed to distributing free LLINs in Uganda through mass campaigns every 3-4 years. 114 
In 2017-18, two brands of LLINs (PermaNet and Olyset) including LLINs with, and without, PBO were 115 
distributed across Uganda. With support from the Ministry of Health, donors, and partners, a large 116 
cluster-randomised trial was embedded within the national LLIN distribution campaign, allowing us 117 
to rigorously evaluate the impact of the LLINs at an unprecedented scale.  118 
 119 
Methods 120 
The trial protocol has been published previously.18  121 
 122 
Study design 123 
Our primary objective was to evaluate the impact of combination LLINs (with PBO), as compared to 124 
conventional LLINs (without PBO), on parasite prevalence in eastern and western Uganda. For this 125 
trial, clusters were defined as one health sub-district (serving approximately 100,000 people); 104 126 
(47%) of 221 health sub-districts nationwide were included, covering 48 districts (figure 1). Clusters 127 
8 
 
were randomly assigned to one of four study arms: (1) PermaNet 3·0 [n=32], (2) Olyset Plus [n=20] 128 
(both PBO LLINs); and (3) PermaNet 2·0 [n=37], (4) Olyset Net [n=15] (both conventional LLINs 129 
without PBO). Following sensitisation of authorities and local communities, baseline cross-sectional 130 
community and entomology surveys were conducted.17,19,20 From 2017ꟷ2018, LLINs were delivered 131 
through a mass-distribution campaign. Cross-sectional community and entomology surveys were 132 
carried out at 6-, 12- and 18-months after net distribution; net durability and bio-efficacy were 133 
assessed at 12 months. The primary outcome was parasite prevalence measured by microscopy in 134 
children aged 2-10 years.  135 
 136 
Study setting 137 
Health sub-districts in eastern and western Uganda, which were not scheduled to receive IRS with 138 
pirimiphos-methyl (Actellic),14 were included in the trial. Districts in the north and east where IRS 139 
was ongoing or planned, were excluded. At baseline, 65% of households owned at least one LLIN, 140 
but only 18% met the WHO definition of adequate coverage (at least one LLIN per two residents).20  141 
Overall, parasite prevalence in children aged 2-10 years was 26%, ranging from 8% in the South West 142 
region to 53% in East Central.17 Very high levels of pyrethroid resistance due to target-site (primarily 143 
Vgsc-L1014S) and metabolic mechanisms (markers Cyp4j5-L43F and Coeae1d) were observed.19  144 
 145 
Assignment of interventions 146 
Initial randomisation 147 
LLINs were procured in advance of the randomisation. We utilised the entire production capacity for 148 
the PBO LLINs due to the scale of the trial; thus, the total number of the four LLIN types varied. 149 
Proportionate randomisation was carried out by a co-investigator based outside of Uganda using 150 
STATA Version 14.2 (StataCorp, Texas, USA), as described previously.18 Briefly, an iterative process 151 
was used to assign net types to each cluster using cumulative probability ranges generated for each 152 
of the four types of nets based on the targeted number of each individual type of net / targeted 153 
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number of total nets and random numbers between 0 and 1 generated for each cluster. The 154 
randomisation was stratified by region, with 66 clusters in the west, and 38 clusters in the east, in 155 
case regional differences in insecticide resistance were found. However, no significant differences in 156 
resistance marker frequency by region or study arm were observed at baseline. LLIN allocation was 157 
not blinded.  158 
 159 
LLIN distribution 160 
The following LLINs were distributed: PermaNet® 3·0 and PermaNet® 2·0 (Vestergaard Frandsen SA, 161 
Denmark), and Olyset® Plus and Olyset® Net (Sumitomo Chemical, Japan). The Ministry of Health, 162 
local government, and partners distributed the assigned LLINs from March 2017 to March 2018, as 163 
part of the national LLIN distribution campaign, according to the net allocation list generated from 164 
the randomisation. Using household registration data collected prior to the campaign, an allocation 165 
formula was applied by the Ministry of Health to determine the number of LLINs each household 166 
should receive (total number of people in the household, divided by two, and rounded up if the 167 
number of household members was uneven). 168 
 169 
Revised randomisation and net allocation 170 
LLINs were delivered in the first 44 clusters (24 PBO and 20 non-PBO) as scheduled. However, the 171 
total number of nets needed was underestimated and additional LLINs had to be procured. 172 
Subsequently, the 60 remaining clusters were re-randomised, using the same process of 173 
proportionate randomisation, resulting in 52 clusters being assigned to each of the two main study 174 
arms (PBO vs non-PBO).18  175 
 176 
Community surveys 177 
Cross-sectional surveys were conducted at 6-, 12-, and 18-months following LLIN distribution by 178 
study staff. Two-stage cluster sampling was applied using enumeration areas as the primary 179 
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sampling unit; ten enumeration areas (defined as a natural village, or urban city block) within each 180 
cluster were randomly selected.18 All households in the selected areas were mapped and assigned an 181 
identification number. A list of randomly selected households was generated for each area. 182 
Households were approached sequentially until five were enrolled from each area (50 households 183 
per cluster, 5,200 per survey). Households were included if: (1) at least one resident was 2-10 years 184 
of age, (2) at least one adult (> 18 years) was present, (3) the adult was usually resident and slept in 185 
the sampled household on the night before the survey, and (4) the adult agreed to provide written, 186 
informed-consent to participate in the survey. Households were excluded if: (1) the dwelling was 187 
destroyed or could not be found, (2) the house was vacant, (3) there was no adult resident home on 188 
more than three occasions.  189 
 190 
Heads of household, or their designate, were asked to complete a household survey questionnaire, 191 
to gather information on households, residents, and LLIN ownership and use.18,20 Children residing in 192 
the household had blood drawn by finger-prick, if they met the following selection criteria: (1) aged 193 
2-10 years, (2) usually resident and slept in the sampled household on the night before the survey, 194 
(3) provision of written informed consent by parent/guardian, (4) provision of assent by child > 8 195 
years of age. Children who could not be located were excluded. Blood samples were taken for a thick 196 
blood smear from all children enrolled; haemoglobin was measured in children aged 2-4 years, as 197 
anaemia is predominant in children under-five in Uganda.21 Participants who had a temperature of > 198 
38.0⁰C, or who reported fever in the past 48 hours, had a rapid diagnostic test performed and were 199 
managed as previously reported.18  200 
 201 
Entomology surveys 202 
In each cluster, ten households were randomly selected for inclusion into the entomology survey 203 
from the list of 50 households enrolled into the community surveys (1,040 per survey). Households 204 
were included if: (1) at least one adult (aged > 18 years) was present; (2) the adult was a usual 205 
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resident who slept in the sampled household on the night before the survey; (3) the adult resident 206 
agreed to provide written informed consent. The household was excluded if no adult resident was 207 
home on more than three occasions. Mosquitoes resting on interior surfaces were collected by 208 
entomology technicians using Prokopack aspirators (John W. Hock Co., USA). A standardised 209 
collection duration of ten minutes per house was used, which was sufficient to mechanically aspirate 210 
mosquitoes from all resting surfaces in a typical house, while minimising disruptions. Female 211 
anopheles mosquitoes were identified phenotypically and stored on silica gel in the field, before 212 
being shipped to the Liverpool School of Tropical Medicine (LSTM) for molecular analysis. 213 
 214 
LLIN assessment 215 
Twelve months after LLINs were distributed, 400 LLINs (100 of each of LLIN type) were withdrawn 216 
(and replaced) from selected households enrolled in the community surveys. Net integrity was 217 
assessed using WHO guidelines.22 LLINs were fitted over a frame and visually examined. The number 218 
and size (length and width) of observed holes was classified into standardised categories based on 219 
hole size. A sub-set of 138 LLINs (35 PermaNet 3·0, 31 Olyset Plus, 38 PermaNet 2·0, 34 Olyset Net) 220 
were selected at random for chemical analysis of insecticide and synergist content using high-221 
performance liquid chromatography (HPLC). LLINs that were withheld from the national distribution 222 
were used as baseline controls (five for each net type). 223 
 224 
Laboratory procedures 225 
Microscopy and haemoglobin testing 226 
Thick blood smears were dried and transported to the Infectious Diseases Research Collaboration 227 
Molecular Research Laboratory in Kampala within seven days for processing and reading. Slides were 228 
stained with 2% Giemsa for 30 minutes and read by experienced laboratory technologists. Parasite 229 
densities were calculated by counting the number of asexual parasites, per 200 leukocytes (or per 230 
500, if the count was less than 10 parasites per 200 leukocytes), assuming a leukocyte count of 231 
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8,000/μl. A thick blood smear was considered negative when the examination of 100 high power 232 
fields did not reveal asexual parasites. For quality control, all slides were read by a second 233 
microscopist and a third reviewer settled discrepant readings, defined as (1) positive versus a 234 
negative thick blood smear, (2) parasite density differing by > 25%. Haemoglobin measurements 235 
were made using a portable HemoCue analyzer (HemoCue, Anglom, Sweden).  236 
 237 
High-performance liquid chromatography 238 
HPLC analysis was performed using standard procedures (supplemental file 1). The quantities of 239 
pyrethroid and PBO were calculated in grams per kilogram of net material from standard curves 240 
established with known concentrations of authenticated standards for PBO, permethrin and 241 
deltamethrin (PESTANAL®, analytical standard, Sigma-Aldrich, UK) and corrected against internal 242 
standard dicyclohexyl phthalate readings.  243 
 244 
Bioassays 245 
Standard WHO cone bioassays were conducted using a standard lab strain of A. gambiae from 246 
Kisumu, western Kenya, which is fully susceptible to both permethrin and deltamethrin.23  In brief, 247 
five unfed 3- to 5-day-old mosquitoes were exposed for three minutes to a sample of each LLIN. 248 
Testing was restricted to fabric from the top of each LLIN to ensure comparability between products. 249 
Knockdown was recorded 60 minutes post-exposure and mortality after 24 hours. Two cone tests 250 
were conducted per net together with appropriate controls.  251 
 252 
Sample size calculations 253 
The study sample size (number of clusters, and allocation of interventions) was determined by the 254 
number of LLINs available and the estimated number of LLINs required per cluster. We aimed to 255 
sample all eligible children aged 2-10 years from 50 households in the 104 clusters in each round of 256 
surveys, estimating up to 10,400 children would be sampled per survey, assuming an average of two 257 
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children aged 2-10 years per household. Assuming a parasite prevalence of 40% in the control arm,24 258 
and coefficient of variation between clusters of 0.3 (derived from the Tanzanian trial),13 we had 80% 259 
power (two-sided significance level of 0·05) to detect a relative reduction in parasite prevalence of at 260 
least 17% (prevalence ratio of 0·83).  261 
 262 
Analytical issues 263 
All data were collected by survey teams using hand-held tablet computers, were transferred daily to 264 
our core data facilities, and were stored on a secure server, as previously described.18 All analyses 265 
were conducted using both an intention-to-treat and ‘as treated’ approach. Before conducting the 266 
final analyses, we decided to present the ‘as treated’ analyses as the main study findings, because 267 
this approach most accurately reflects the type of LLINs actually received in each cluster, and was 268 
deemed appropriate for this unique, large-scale, effectiveness study. For the ‘as treated’ analysis, 269 
clusters were grouped by study arm according to the type of LLINs received according to household 270 
data from the 6-month survey. For clusters with mixed LLIN distribution, the number of nets from 271 
the dominant type received (numerator) was divided by the total number of the 4 study LLIN types 272 
received in that cluster (denominator); non-study nets were excluded. To be included in the ‘as 273 
treated’ analyses, the proportion of the dominant net had to be > 75%; clusters in which the 274 
dominant net type received was < 75% were excluded. Analyses for outcomes measured at multiple 275 
time points following LLIN distribution were conducted independently. No allowance was made for 276 
multiplicity of testing in the analyses. An individual-level approach to the analysis was used due to 277 
the large number of clusters per arm. For all analyses, a p-value < 0.05 was considered statistically 278 
significant.  279 
 280 
The primary outcome was parasite prevalence, defined as the proportion of children 2-10 years of 281 
age with asexual parasites detected by microscopy. For comparison of the primary outcome 282 
between study arms, a log-binomial regression model was used with generalized estimating 283 
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equations to allow for within-cluster correlations and adjustment for baseline cluster-level parasite 284 
prevalence. The effect of the intervention was expressed as the prevalence ratio (prevalence in the 285 
intervention arm/prevalence in the control arm).  286 
 287 
Secondary outcomes included prevalence of any anaemia (haemoglobin < 11 g/dL), 288 
moderate/severe anaemia (haemoglobin < 10 g/dL), vector density (the number of female 289 
Anopheles collected per household), and measures of LLIN ownership (the proportion of households 290 
that owned at least one LLIN), adequate LLIN coverage (the proportion of households that owned at 291 
least one LLIN for every two occupants), LLIN use (the proportion of household residents who slept 292 
under an LLIN the previous night), LLIN integrity (number and estimated area of holes in the net 293 
fabric), and bio-efficacy (proportion of susceptible female anopheles mosquitoes surviving a 294 
standard WHO cone test exposure). HPLC results for withdrawn LLINs and their unused controls 295 
were compared using the Wilcoxon rank sum test. 296 
 297 
For secondary outcomes measured as proportions, the same analytical approach was used as for the 298 
primary outcome. For comparison of vector density and LLIN integrity between treatment arms, a 299 
negative binomial regression model was used with generalized estimating equations to allow for 300 
within-cluster correlations and adjustment for baseline cluster-level vector density. The effect of the 301 
intervention was expressed as the density ratio (density in the intervention arm/density in the 302 
control arm). Analyses of anaemia and vector density included adjustment for baseline cluster-level 303 
values. 304 
 305 
Research ethics approval 306 
The trial was approved by the Ugandan National Council for Science and Technology (UNCST Ref HS 307 
2176), Makerere University School of Medicine Research & Ethics Committee (SOMREC 2016-133), 308 
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London School of Hygiene & Tropical Medicine Ethics Committee (LSHTM Ref 12019), and the 309 
Liverpool School of Tropical Medicine (LSTM Ref 16-072), which sponsored the study. 310 
 311 
Role of the funder 312 
The content of the manuscript is solely the responsibility of the authors. The funders played no role 313 
in data collection, analysis, interpretation, writing of the manuscript or the decision to submit. 314 
 315 
Results 316 
LLIN delivery 317 
Of the 104 clusters (figure 2), 52 were randomised to each study arm (non-PBO LLINs vs PBO LLINs) 318 
and were included in the intention-to-treat analysis. For the ‘as treated’ analysis, three clusters were 319 
excluded because no dominant LLIN type was received, and four were reassigned to a different 320 
study arm (figure 2); thus, 52 non-PBO LLIN clusters (39 PermaNet 2·0, 13 Olyset Net) and 49 PBO 321 
LLIN clusters (31 PermaNet 3·0, 18 Olyset Plus) were included.  322 
 323 
Baseline survey 324 
Baseline cross-sectional community and entomology surveys were carried out from March to June 325 
2017 (table 1), and were published previously.17,19,20 Characteristics of households (n=5,196, median 326 
50 per cluster, range 48ꟷ50) were similar across study arms. Most households were constructed of 327 
traditional materials (73%) and owned at least one LLIN (65%), but few were adequately covered 328 
with LLINs, defined as one LLIN for every two residents (18%). In children aged 2-10 years tested for 329 
parasitaemia (n=8,836, median 83 per cluster, range 56ꟷ121), median cluster-level parasite 330 
prevalence (19%) was similar between the study arms, but ranged widely (0%ꟷ77%), resulting in a 331 
coefficient of variation of 0.86, which was not anticipated. When the study population was stratified 332 
by manufacturer, median parasitaemia was higher in the PermaNet arms than in the Olyset arms 333 
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(25% vs. 10%, p=0·03). In children aged 2-4 years tested for anaemia (n=3,762, median 36 per 334 
cluster, range 11ꟷ57), median anaemia prevalence (31%) was similar between the study arms. In 335 
households included in the entomology survey (n=1,028, median 10 per cluster, range 8ꟷ10), 336 
median household vector density (0·4 female anopheles/house) was also similar between the study 337 
arms. 338 
 339 
LLIN ownership, coverage and use 340 
Cross-sectional surveys were carried out at 6, 12, and 18 months after LLIN distribution, from 341 
September 2017 to September 2019 (figure 2). Trends in LLIN ownership, coverage and use were 342 
similar in both study arms (supplemental file 3). Nearly all households reported owning at least one 343 
LLIN at 6 months (97%). LLIN ownership remained high at 12 months (95%), and at 18 months (91%). 344 
In contrast, at 6 months, adequate coverage of LLINs (one LLIN for every two residents) had 345 
increased markedly from baseline (18% to 71%), but decreased at 12 months (63%) and fell even 346 
further at 18 months (51%), indicating that LLIN attrition post-distribution is an issue. In the 6-month 347 
community surveys, most household residents reported sleeping under a LLIN the previous night 348 
(85·4%); reported use of LLINs remained high at 12 months (78·6%) and at 18 months (73·1%). 349 
 350 
LLIN assessment 351 
Nets withdrawn from households participating in the community surveys were analysed for net 352 
durability. After 12 months, fabric integrity of all LLIN types had degraded markedly; 73% of LLINs 353 
were found to have at least one hole, with an average of ten holes per net. Over two-thirds of LLINs 354 
were in good condition as per WHO classification (total area of holes/net <80cm2): PermaNet 2·0: 355 
79%, PermaNet 3·0: 71%, Olyset Net: 68%, Olyset Plus: 67%.  356 
 357 
17 
 
HPLC analysis revealed that all unused nets had insecticide and PBO concentrations within the 358 
manufacturers’ specifications. After 12 months, withdrawn LLINs had less insecticide than unused 359 
nets for PermaNet 3·0 (p=0·04), Olyset Net (p<0·001), and Olyset Plus (p=0·001). The proportion of 360 
used nets found to have less than the manufacturers’ declared minimum insecticide concentration 361 
for a new net was as follows: PermaNet 2·0: 45%; PermaNet 3·0: 3%; Olyset Net: 44%; Olyset Plus: 362 
55%. In PBO LLINs withdrawn at 12 months, PBO concentrations were significantly lower than in 363 
unused nets with 80·0% of PermaNet 3·0 (p<0·001) and 90% of Olyset Plus (p<0·001) having less 364 
than the manufacturers minimum target dose of PBO. No data were collected on frequency of LLIN 365 
washing, which might contribute to insecticide loss. 366 
 367 
In a bio-efficacy study of the withdrawn LLINs using WHO cone assays and a pyrethroid-susceptible 368 
strain of Anopheles gambiae s.s., all LLINs met the WHO criteria for efficacy (>80% mortality 24 369 
hours post-exposure). The control-corrected mortality estimates for each LLIN type included:  370 
PermaNet 2·0: 98% (95% CI: 97·3–99·3%); PermaNet 3·0: 100% (95% CI: 99·4–100%); Olyset Net: 371 
94% (95% CI: 91·9–95·4%) and Olyset Plus: 98% (95% CI: 96·6–99·2%). 372 
 373 
Impact on primary outcome: parasite prevalence 374 
In the ‘as treated’ analysis, parasite prevalence was lower in the PBO arm than the non-PBO arm at 375 
6, 12, and 18 months after LLIN distribution (table 2). Parasite prevalence at 6 months was 11% in 376 
the PBO arm vs 15% in the non-PBO arm (prevalence ratio adjusted for baseline values [PR] 0·74 377 
[95% CI: 0·62–0·87], p<0·001). Similar results were observed at the 12- and 18-month timepoints. In 378 
both the PBO and non-PBO arms, parasite prevalence decreased from baseline (supplemental file 4); 379 
the changes from baseline were greater for both arms than the differences between the study arms. 380 
 381 
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In the sub-group analysis stratified by brand, parasite prevalence was lower in the PermaNet 3·0 382 
(with PBO) arm than the PermaNet 2·0 (non-PBO) arm at 6 and 12 months, but not at 18 months 383 
(table 2). The greatest impact was observed at the 6-month time-point (12%vs 16%, PR 0·67 [95% CI: 384 
0·56–0·81], p<0·001). For Olyset, parasite prevalence was lower in the Olyset Plus (with PBO) arm 385 
than the Olyset Net (non-PBO) arm only at 12 months (4% vs 7%, PR 0·62 [95% CI: 0·46–0·85], 386 
p=0·003) and 18 months (6% vs 13%, PR 0·66 [95% CI: 0·47–0·93], p=0·02). 387 
 388 
In the sub-group analysis stratified by region (supplemental file 2), in the East, parasite prevalence 389 
was lower in the PBO arm than the non-PBO arm at 6 months (16% vs 22%, PR 0·66 [95% CI: 0·53–390 
0·82], p<0·001) and 12 months (18% vs 21%, PR 0·69 [95% CI: 0·58–0·82], p<0·001), but not at 18 391 
months. In contrast, in the West, parasite prevalence was lower in the PBO arm than the non-PBO 392 
arm only at 18 months (4% vs 10%, PR 0·56 [95% CI: 0·42–0·74), p<0·001.  393 
 394 
Impact on secondary outcomes: anaemia 395 
In the ‘as treated’ analysis, the prevalence of any anaemia (haemoglobin < 11 g/dL) at 6 months was 396 
lower in the PBO arm than the non-PBO arm (19% vs 26%, PR 0·72 [95% CI: 0·54ꟷ0·95], p=0·02). 397 
Although a similar pattern was observed at 12 and 18 months, differences were not statistically 398 
significant (table 4). In the sub-group analysis stratified by brand, no statistically significant 399 
differences in prevalence of anaemia were seen between the PermaNet arms at any timepoint. 400 
However, anaemia prevalence was significantly lower in the Olyset Plus (with PBO) arm than the 401 
Olyset Net (non-PBO) arm at 6 and 18 months. No differences in the prevalence of moderate/severe 402 
anaemia (haemoglobin < 10 g/dL) were observed between the study arms (supplemental file 5).  403 
  404 
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Impact on secondary outcomes: vector density 405 
Vector density of all female anopheles was lower in the PBO arm than the non-PBO arm at all three 406 
timepoints (table 5). In the ‘as treated’ analysis, 82 mosquitoes were identified at 6 months in 490 407 
household collections in the PBO arm, compared to 363 mosquitoes in 517 collections in the non-408 
PBO arm (density ratio [DR] 0·14 [95% CI: 0·09ꟷ0·22], p<0·001). At 12 and 18 months, vector density 409 
remained lower in the PBO arm, although the number of mosquitoes collected increased in both 410 
arms. In the sub-group analysis, vector density was lower in the PBO than the non-PBO arm at all 411 
timepoints for both PermaNet and Olyset nets.  412 
 413 
Discussion  414 
The results of this innovative, large-scale, cluster-randomised trial suggest that although both PBO 415 
and non-PBO LLINs effectively reduced parasite prevalence from baseline, PBO LLINs provided 416 
superior protection against malaria in the setting of high-level pyrethroid resistance. In the ‘as 417 
treated’ analysis, PBO LLINs were associated with lower parasite prevalence in children aged 2-10 418 
years, compared to conventional LLINs, up to 18 months after distribution. These findings are 419 
supported by the secondary outcomes, particularly vector density. To ensure community-level 420 
benefits of LLINs, the WHO recommends that countries aim for universal LLIN coverage by 421 
distributing nets free-of-charge through mass campaigns conducted every three years, 422 
supplemented by continuous distribution through different channels.25 Results from this trial,20 and 423 
evidence from elsewhere,26,27 raise concerns about the three-year lifespan of LLINs. Strategies for 424 
achieving and maintaining high LLIN coverage, including more frequent mass campaigns, and 425 
expanding routine distribution channels, must be considered.  426 
 427 
Although insecticide resistance poses a major threat to vector control,4 the impact of pyrethroid 428 
resistance on the effectiveness of LLINs is less clear.28  We found that PBO LLINs were more effective, 429 
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but that even non-PBO LLINs were associated with lower parasite prevalence than at baseline at all 430 
timepoints. The findings are consistent with prospective cohort studies conducted in Benin, 431 
Cameroon, India, Kenya and Sudan, which found no evidence of an association between pyrethroid 432 
resistance (as measured by WHO bioassays) and parasite prevalence or malaria incidence in 433 
children.28 Given this, when and where should PBO nets be used? PBO LLINs received a conditional 434 
endorsement as a new class of vector control products by WHO in 2017, following review of the data 435 
from the Tanzanian trial.14  Full endorsement is contingent upon the Vector Control Advisory Group 436 
reviewing data from a second epidemiological trial; we hope that the data presented here will 437 
support a full endorsement. Interim guidelines for the deployment of PBO LLINs were drawn up 438 
following experimental hut trials, the Tanzanian cluster randomised control trial, and a series of 439 
modelling studies.12-14,29  Modelling predicted that the greatest impact of PBO LLINs would be in 440 
areas where pyrethroid resistance was deemed to be at an ‘intermediate level’; defined as mosquito 441 
mortality of 10ꟷ80% after exposure to a pyrethroid insecticide in a standard assay and mediated at 442 
least in part by cytochrome P450s.29  In our study area, WHO-assay based estimates of mortality are 443 
at or below these thresholds, consistent with higher-level insecticide resistance.30,31 Moreover, 444 
studies suggest that cytochrome P450-mediated insecticide resistance is near ubiquitous in both An. 445 
gambiae and An. funestus.32,33  These results, demonstrating superiority of PBO LLINs in the setting of 446 
high-level pyrethroid resistance, suggest that the range of endemicities and levels of resistance 447 
levels for which PBO LLINs are recommended may need to be expanded.  448 
 449 
Despite the many strengths of this study, it also had some limitations. First, the trial was not 450 
powered to directly compare the different LLIN brands (PermaNet vs Olyset), which prevents us 451 
from drawing any conclusions about the superiority of either brand. Our sub-group analyses, 452 
stratified by manufacturer and region, suggest some differences in LLIN performance. However, 453 
these analyses are limited by small sample size, uneven distribution of the LLIN brands, and 454 
imbalances in the distribution of LLINs between regions. Second, we used parasite prevalence rather 455 
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than malaria incidence as the primary outcome measure. Although incidence is considered the gold 456 
standard for measuring malaria burden, we lacked the financial resources to measure incidence in 457 
this study. Third, the distribution of LLINs in this study was imperfect. LLINs were distributed over 12 458 
months. Although malaria transmission in Uganda is seasonal, we think that prolonged distribution is 459 
unlikely to have resulted in bias, because the trial was randomised.  Considering the 101 clusters 460 
included in the ‘as treated’ analyses, 93 (92%) had 85-100% of the dominant LLIN brand, while 8 (8%) 461 
had 75-84%, possibly due to errors in net distribution, movement of nets between clusters, or 462 
reporting errors. Errors in net distribution occurred when the number of allocated LLINs shipped to 463 
the districts was insufficient to achieve universal coverage, requiring additional LLINs to be sourced 464 
from neighbouring districts to cover shortages, which may have been different than the originally 465 
allocated LLIN type. However, this low-level contamination would have likely biased towards the 466 
null. Fourth, we relied on self-report to measure LLIN use. At 18 months, although adequate LLIN 467 
coverage fell markedly in both study arms, LLIN use remained fairly high. It is possible that 468 
households that retained their nets may have been more likely to value and use the LLINs, or that 469 
three or more residents slept under the same LLIN, but reporting bias may also be a factor; residents 470 
may report using LLINs because they believe this to be the correct answer.  Fifth, we decided before 471 
conducting the final analyses, as outlined in our statistical analysis plan, to use the results of the ‘as 472 
treated’ analysis as our primary results. Although we recognise that employing an intention-to-treat 473 
approach for the primary analysis is standard practice, given the exceptional nature of this trial 474 
(large-scale, effectiveness trial of a national LLIN distribution campaign), we opted to report the ‘as 475 
treated’ results as the main outcome as these results reflect the LLINs that were actually distributed 476 
in each cluster.  Sixth, we used prokopack aspirators to collect mosquitoes, not the more commonly 477 
used Centers for Disease Control light traps or human landing catches. Although this may be 478 
considered a limitation, we view this as a strength, as using aspirators allowed us to sample 479 
mosquitoes in all clusters, increasing the granularity of our evaluation and mirroring the 480 
epidemiological outcomes. Collecting mosquitoes using prokopack aspirators proved to be a 481 
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pragmatic, cost-effective, scalable and sensitive approach and should be considered for future 482 
intervention assessments. Finally, we did not assess the cost-effectiveness of PBO LLINs, which is an 483 
important question for policy makers.  484 
 485 
Conclusions 486 
In this pragmatic, cluster-randomised trial, embedded within a national LLIN distribution campaign, 487 
we found that PBO LLINs were more effective than conventional LLINs in Uganda, where resistance 488 
to pyrethroid insecticides is high. This study makes an important contribution to the limited 489 
evidence-base on the use of PBO LLINs. Our results highlight that conventional LLINs provide 490 
protection and may still have a role in vector control programmes in settings where insecticide 491 
resistance and malaria transmission are lower. Future studies should investigate the cost-492 
effectiveness of PBO LLINs, the effectiveness of new generation LLINs including those with two 493 
active ingredients, and approaches for integrating LLINs with IRS and other new malaria control 494 
tools, as these become available.  495 
496 
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FIGURE LEGEND 620 
 621 
Figure 1: Map of study area. The study included 104 clusters, defined as one health sub-district.  622 
 623 
Figure 2: Trial profile. LLIN=long-lasting insecticidal net. PBO=piperonyl butoxide. Hb=haemoglobin.  624 
 625 
 626 
 
Table 1. Baseline characteristics  
 
Characteristic 
Combined study arms Individual study arms 
Non-PBO LLIN PBO LLIN 
PermaNet 2·0 
Non-PBO LLIN 
PermaNet 3·0 
PBO LLIN 
Olyset Net 
Non-PBO LLIN 
Olyset Plus 
PBO LLIN 
Number of clusters 52 52 37 32 15 20 
Eastern region 17 21 13 16 4 5 
Western region 35 31 24 16 11 15 
Number of households surveyed 2598 2598 1849 1598 749 1000 
Household in the lowest tertile of wealth, mean (SD) a 33% (17%) 34% (20%) 30% (16%) 35% (20%) 39% (20%) 33% (21%) 
Households with modern house construction, mean (SD) a 26% (21%) 28% (22%) 29% (21%) 28% (22%) 19% (21%) 28% (24%) 
Households with at least 1 LLIN, mean (SD) a 64% (14%) 66% (14%) 64% (13%) 65% (13%) 65% (18%) 69% (15%) 
Households with adequate LLINs, mean (SD) a 17% (11%) 19% (12%) 16% (11%) 17% (11%) 19% (12%) 21% (13%) 
Number of children 2-10 years tested for parasitaemia 4328 4506 3134 2845 1194 1661 
Parasite prevalence children 2-10 years, median (IQR) a 19% (10-42%) 19% (4-40%) 24% (13-42%) 25% (7-42%) 16% (2-38%) 8% (3-34%) 
Number of children 2-4 years tested for anaemia 1865 1897 1332 1219 533 678 
Anaemia prevalence children 2-4 years, median (IQR)  a 35% (23-45%) 28% (20-44%) 36% (25-45%) 27% (20-42%) 28% (17-36%) 29% (20-48%) 
Number of  households selected for entomological collections 514 514 365 316 149 198 
Household vector density, median (IQR)  b 0·3 (0-2·5) 0·4 (0-6·9) 0·3 (0-2·6) 0·8 (0·2-10·7) 0·3 (0-1·8) 0·1 (0-3·1) 
a Proportions at the level of each cluster 
b Mean values at the level of each cluster  
 
  
  
Table 2. Efficacy analysis of parasite prevalence  
Duration following 
the intervention 
Study arm 
Intention-to-treat analysis As treated analysis 
n/N (%) PR (95% CI) p-value n/N (%) PR (95% CI) p-value 
6 months  
Non-PBO LLIN 552/3867 (14%) reference - 556/3844 (15%) reference - 
PBO LLIN 418/3798 (11%) 0·78 (0·66-0·92) 0.004 386/3614 (11%) 0·74 (0·62-0·87) 0.0003 
12 months  
Non-PBO LLIN 486/3791 (13%) reference - 493/3802 (13%) reference - 
PBO LLIN 427/3918 (11%) 0·80 (0·68-0·95) 0.009 392/3702 (11%) 0·73 (0·63-0·85) 0.0001 
18 months  
Non-PBO LLIN 544/3980 (14%) reference - 558/3976 (14%) reference - 
PBO LLIN 474/3915 (12%) 0·94 (0·80-1·10) 0.46 437/3708 (12%) 0·84 (0·72-0·98) 0.03 
6 months  
PermaNet 2·0 a 440/2713 (16%) reference - 451/2836 (16%) reference - 
PermaNet 3·0 b 275/2385 (12%) 0·70 (0·57-0·85) 0.0002 271/2334 (12%) 0·67 (0·56-0·81) <0.0001 
12 months  
PermaNet 2·0 a 412/2760 (15%) reference - 427/2906 (15%) reference - 
PermaNet 3·0 b 346/2532 (14%) 0·83 (0·69-0·99) 0·04 343/2456 (14%) 0·76 (0·65-0·90) 0·001 
18 months  
PermaNet 2·0 a 410/2825 (15%) reference - 429/2966 (15%) reference - 
PermaNet 3·0 b 361/2526 (14%) 0·98 (0·82-1·18) 0·85 356/2440 (15%) 0·90 (0·76-1·07) 0·22 
6 months  
Olyset Net a 112/1154 (10%) reference - 105/1008 (10%) reference - 
Olyset Plus b 143/1413 (10%) 1·08 (0·77-1·51) 0·67 115/1280 (9%) 0·99 (0·69-1·42) 0·96 
12 months  
Olyset Net a 74/1031 (7%) reference - 66/896 (7%) reference - 
Olyset Plus b 81/1386 (6%) 0·82 (0·56-1·20) 0·30 49/1246 (4%) 0·62 (0·46-0·85) 0·003 
18 months  
Olyset Net a 134/1155 (12%) reference - 129/1010 (13%) reference - 
Olyset Plus b 113/1389 (8%) 0·78 (0·58-1·04) 0·09 81/1268 (6%) 0·66 (0·47-0·93) 0·02 
a Non-PBO LLIN 
b PBO LLIN  
 
 Table 3. Efficacy analysis of anaemia (haemoglobin < 11 gm/dL) prevalence  
Duration following 
the intervention 
Study arm 
Intention-to-treat analysis As treated analysis 
n/N (%) PR (95% CI) p-value n/N (%) PR (95% CI) p-value 
6 months  
Non-PBO LLIN 416/1639 (25%) reference - 433/1647 (26%) reference - 
PBO LLIN 307/1609 (19%) 0·76 (0·57-1·01) 0·06 283/1509 (19%) 0·72 (0·54-0·95) 0·02 
12 months  
Non-PBO LLIN 435/1691 (26%) reference - 450/1692 (27%) reference - 
PBO LLIN 345/1681 (21%) 0·83 (0·60-1·14) 0·25 325/1584 (21%) 0·79 (0·57-1·08) 0·14 
18 months  
Non-PBO LLIN 414/1657 (25%) reference - 416/1671 (25%) reference - 
PBO LLIN 308/1704 (18%) 0·76 (0·53-1·09) 0·13 292/1607 (18%) 0·75 (0·52-1·07) 0·11 
6 months  
PermaNet 2·0 a 297/1193 (25%) reference - 327/1259 (26%) reference - 
PermaNet 3·0 b 234/1072 (22%) 0·94 (0·68-1·29) 0·70 220/1035 (21%) 0·85 (0·62-1·16) 0·31 
12 months  
PermaNet 2·0 a 335/1223 (27%) reference - 357/1282 (28%) reference - 
PermaNet 3·0 b 252/1101 (23%) 0·89 (0·60-1·31) 0·56 238/1060 (23%) 0·84 (0·57-1·23) 0·36 
18 months  
PermaNet 2·0 a 283/1211 (23%) reference - 299/1281 (23%) reference - 
PermaNet 3·0 b 228/1135 (20%) 0·93 (0·62-1·38) 0·71 216/1092 (20%) 0·86 (0·58-1·29) 0·48 
6 months  
Olyset Net a 119/446 (27%) reference - 106/388 (27%) reference - 
Olyset Plus b 73/537 (14%) 0·48 (0·28-0·84) 0·009 63/474 (13%) 0·46 (0·26-0·80) 0·006 
12 months  
Olyset Net a 100/468 (21%) reference - 93/410 (23%) reference - 
Olyset Plus b 93/580 (16%) 0·76 (0·44-1·31) 0·32 87/524 (17%) 0·74 (0·42-1·29) 0·29 
18 months  
Olyset Net a 131/446 (29%) reference - 117/390 (30%) reference - 
Olyset Plus b 80/569 (14%) 0·48 (0·24-1·00) 0·05 76/515 (15%) 0·46 (0·23-0·96) 0·04 
a Non-PBO LLIN 
b PBO LLIN  
 
  
Table 4. Efficacy analysis of vector density  
Duration following 
the intervention 
Study arm 
Intention-to-treat analysis As treated analysis 
# of female 
mosquitoes 
# of 
collections 
DR (95% CI) p-value 
# of 
mosquitoes 
# of 
collections 
DR (95% CI) p-value 
6 months  
Non-PBO LLIN 333 517 reference - 363 517 reference - 
PBO LLIN 113 520 0·27 (0·17-0·41) <0.0001 82 490 0·14 (0·09-0·22) <0.0001 
12 months  
Non-PBO LLIN 563 520 reference - 669 520 reference - 
PBO LLIN 345 520 0·57 (0·41-0·79) 0.0007 202 490 0·17 (0·12-0·25) <0.0001 
18 months  
Non-PBO LLIN 821 520 reference - 729 520 reference - 
PBO LLIN 536 520 0·25 (0·18-0·34) <0.0001 523 490 0·25 (0·18-0·35) <0.0001 
6 months  
PermaNet 2·0 a 229 368 reference - 259 388 reference - 
PermaNet 3·0 b 53 320 0·14 (0·08-0·24) <0.0001 53 310 0·13 (0·08-0·23) <0.0001 
12 months  
PermaNet 2·0 a 418 370 reference - 526 390 reference - 
PermaNet 3·0 b 165 320 0·23 (0·16-0·33) <0.0001 161 310 0·18 (0·12-0·27) <0.0001 
18 months  
PermaNet 2·0 a 734 370 reference - 643 390 reference - 
PermaNet 3·0 b 488 320 0·21 (0·15-0·30) <0.0001 488 310 0·25 (0·17-0·36) <0.0001 
6 months  
Olyset Net a 104 149 reference - 104 129 reference - 
Olyset Plus b 60 200 0·65 (0·32-1·30) 0·23 29 180 0·19 (0·10-0·36) <0.0001 
12 months  
Olyset Net a 145 150 reference - 143 130 reference - 
Olyset Plus b 180 200 1·30 (0·78-2·18) 0·32 41 180 0·16 (0·09-0·28) <0.0001 
18 months  
Olyset Net a 87 150 reference - 86 130 reference - 
Olyset Plus b 48 200 0·43 (0·24-0·78) 0·006 35 180 0·27 (0·15-0·47) <0.0001 
a Non-PBO LLIN 
b PBO LLIN  
 

 37 clusters randomised to 
PermaNet 2.0 
15 clusters randomised to 
Olyset Nets 
52 clusters randomised to non-PBO LLINs 
1 cluster excluded 
0 reassigned 
 
39 clusters received  
PermaNet 2.0 
13 clusters received  
Olyset Nets 
52 received non-PBO LLINs (per-protocol analysis) 
0 clusters excluded  
2 reassigned  
   1 PermaNet 2.0 
   1 PermaNet 3.0 
 
104 clusters randomised  
66 in Western region 
38 in Eastern region 
 
32 clusters randomised to 
PermaNet 3.0 
20 clusters randomised to 
Olyset Plus 
52 clusters randomised to PBO LLINs 
31 clusters received  
PermaNet 3.0 
18 clusters received  
Olyset Plus 
49 received PBO LLINs (per-protocol analysis) 
1 cluster excluded  
1 reassigned  
   1 PermaNet 2.0 
 
1 cluster excluded  
1 reassigned  
   1 PermaNet 2.0 
 
Community surveys – household recruitment 
6-month survey 
7721 screened 
   5121 excluded 
      2600 enrolled 
            1 excluded  
         2599 analysed 
 
12-month survey 
8539 screened 
   5939 excluded  
      2600 enrolled 
            0 excluded  
         2600 analysed 
 
18-month survey 
8234 screened 
   5634 excluded 
      2600 enrolled 
             0 excluded 
         2600 analysed 
 
Community surveys – household recruitment 
 
6-month survey 
7569 screened 
   4969 excluded 
      2600 enrolled 
            3 excluded 
         2597 analysed 
 
12-month survey 
8003 screened 
   5403 excluded 
      2600 enrolled 
             0 excluded  
         2600 analysed 
 
18-month survey 
8129 screened 
   5529 excluded 
      2600 enrolled 
            0 excluded 
         2600 analysed 
 
Clinical surveys of children aged 2-10 years 
6-month survey 
5185 screened 
   1315 excluded 
      3869 enrolled 
             2 missing BS 
         3867 analysed 
 
12-month survey 
5236 screened 
   1445 excluded 
      3791 enrolled 
            0 missing BS 
         3791 analysed 
 
18-month survey 
5234 screened 
   1252 excluded 
      3982 enrolled 
             2 missing BS         
         3980 analysed 
 
Haemoglobin testing in children aged 2-10 years 
6-month survey 
1641 eligible 
      2 missing Hb 
   1639 analysed 
 
12-month survey 
1692 eligible 
      1 missing Hb 
   1691 analysed 
 
18-month survey 
1657 eligible 
      0 missing Hb 
   1657 analysed 
 
Clinical surveys of children aged 2-10 years 
 
6-month survey 
5264 screened 
   1463 excluded 
      3801 enrolled 
             3 missing BS          
         3798 analysed 
 
12-month survey 
5302 screened 
   1383 excluded 
      3919 enrolled 
             1 missing BS 
         3918 analysed 
 
18-month survey 
5331 screened 
   1415 excluded 
      3916 enrolled 
            1 missing BS 
         3915 analysed 
 
Haemoglobin testing in children aged 2-10 years 
6-month survey 
1615 eligible 
      6 missing Hb 
   1609 analysed 
 
12-month survey 
1688 eligible 
      7 missing Hb 
   1681 analysed 
 
18-month survey 
1708 eligible 
      4 missing Hb 
   1704 analysed 
 
Households selected for entomology surveillance 
6-month survey 
2599 eligible 
   517 enrolled 
   
12-month survey 
2600 eligible 
   520 enrolled 
 
18-month survey 
2600 eligible 
   520 enrolled 
 
Households selected for entomology surveillance 
6-month survey 
2597 eligible 
   520 enrolled 
   
12-month survey 
2600 eligible 
   520 enrolled 
 
18-month survey 
2600 eligible 
   520 enrolled 
 
